Clinical Trial: NCT06497556
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Official Title
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Intervention / Treatment
- Drug: Divarasib
- Drug: Sotorasib
- Drug: Adagrasib
Other Study ID Numbers
- BO45217
- 2024-510908-37-00
Start Date (Actual)
2024-09-23
Primary Completion Date (Actual)
2026-05-19
Study Completion Date (Estimated)
2029-11-30
Enrollment (Actual)
338
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-09-16 |
Study Overview
Brief Summary
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Official Title
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Intervention / Treatment
- Drug: Divarasib
- Drug: Sotorasib
- Drug: Adagrasib
Other Study ID Numbers
- BO45217
- 2024-510908-37-00
Start Date (Actual)
2024-09-23
Primary Completion Date (Actual)
2026-05-19
Study Completion Date (Estimated)
2029-11-30
Enrollment (Actual)
338
Study Type
Interventional
Phase
Phase 3